Indefinite Delivery Contract SPE2DR25D9833

DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was awarded a single-award Indefinite Delivery Contract (IDC) by the Defense Logistics Agency on November 13, 2025, under the Pharmaceutical Prime Vendor Global Program Generation V initiative. The contract carries a ceiling value of $5.0 million with an ultimate completion date of December 31, 2036, structured as a 30-month base period followed by three 30-month option periods. The contract authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products and medical consumables, including branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, specialty pharmaceuticals, and medical consumables to support Department of Defense healthcare facilities worldwide. Notable product categories supplied include oncology treatments, immunosuppressants, biologic agents, emergency medications, specialty surgical products, contraceptive devices, vaccines, antibiotics, antivirals, and pain management drugs.

The underlying Pharmaceutical Prime Vendor Global Program Generation V solicitation, posted as a pre-solicitation notice on February 1, 2024, represented part of a $30.3 billion government-wide acquisition strategy designed to establish pharmaceutical supply contracts on a regional basis with multiple contractors to ensure worldwide pharmaceutical support to Department of Defense customers. The original solicitation anticipated awards to responsive and responsible offerors whose proposals were technically acceptable and offered the lowest overall price based on distribution fees, with multiple awards planned across distinct geographic regions including North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet line items. The procurement specified that both primary and backup suppliers would provide separate distribution fees for branded/generic and specialty pharmaceuticals to support normal and contingency operations globally. No set-asides were designated for this unrestricted federal procurement, and all awards remain funded exclusively by the Defense Logistics Agency and its Medical Supply Chain division.